Secţiunea 2 - METODOLOGIE DE ELABORARE ŞI REVIZIE - Ghid din 2019 privind terapia menopauzei
M.Of. 738 bis
În vigoare Versiune de la: 10 Septembrie 2019
SECŢIUNEA 2:METODOLOGIE DE ELABORARE ŞI REVIZIE
1.Asociaţia Medicală de Menopauză din România (AMMR) (2004) - Consensul privind terapia hormonală pentru menopauză al Asociaţiei Medicale de Menopauză din România. Sinaia, 27-29 februarie 2004
2.Lewiecki EM, Watts NB, McClung MR, et al. (2004) - Official positions of the international society for clinical densitometry. J. Clin. Endocrinol. Metab. 2004; 89(8), 3651-3655 (The diagnostic criteria for premenopausal osteoporosis are contained in these guidelines. The need for additional fracture risks beyond low Z-scores is also discussed)
3.Canonico M, Oger E, Plu-Bureau G, et al.(2007) - Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007; 115:840-845.
4.National Osteoporosis Foundation. What Women Need to Know. National Osteoporosis Foundation, Washington, DC, USA (2013).
5.Hodis HN, Shoupe D, Azen SP, Henderson VW, et al. (2014) - Testing the menopausal hormone therapy timing hypothesis: the Early versus Late Intervention Trial with Estradiol (ELITE). Circulation. 2014; 22(4):391-401.
6.Stuenkel CA, Davis SR, Gompel A, et al-(2015) Treatment of symptoms of the Menopause. An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2015; 100; 3975 http://www.cancer.gov/bcrisktool/.
7.Barber RJ, Panay N, Fenton A, and the IMS Writing Group (2016) - . IMS Recommendations on womem's midlife health and menopause hormone therapy. Climacteric. 2016; 19 (2): 109-150
8.Bassuk SS, Manson JE. The timing hypothesis: Do coronary risks of menopausal hormone therapy vary by age or time since menopause onset? Metabolism, 2016; 65(5):794-803.
9.De Villiers TJ, Hall JE, Pinkerton JV, Cerdas Perez S, Rees M, Yang C, et al. Revised global consensus statement on menopausal hormone therapy. Climacteric. 2016 Aug. 19(4):313-5.
10.The Nams 2017 - Hormone therapy position statement advisory panel. The 2017 hormone therapy position statement of the north amenrican menopause society. Menopause 2017; 24:728.
11.Haelle T. (2016) - New Menopause Guidelines Update HT Safety Evidence. Medscape Medical News. August 18, 2016. Available at http://www.medscape.com/viewarticle/867600.
12.Barber RJ, Panay N, Fenton A, and the IMS Writing Group (2016) - IMS Recommendations on womem's midlife health and menopause hormone therapy. Climacteric. 2016; 19 (2): 109-150
13.Marjoribanks J, Farquhar C, Roberts H, Lethaby A, Lee J (Gynecology and Fertility Group) (2017) - Long-term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database of Systematic Reviews, 2017, CD004143.
14.Mikkila TS, Savolainen-Peltonen H et al. New evidence for cardiac benefic of postmenopausal hormone therapy. Climacteric; 20(1):5-10.
15.US preventive services task force. Grossman DC, Curry SJ et al. Hormone therapy for the primary prevention of chronic conditions in postmenopausal women: Recommendation statement. Jama 2017 Dec 12.318(22):2224-2233.